Comparison of 150 IU and 225 IU of follitropin-β in a fixed-dose regimen for ovarian stimulation using a depot formulation of GnRH agonist: A prospective randomized clinical trial

Jornal Brasileiro de Reproducao Assistida

Volumn 10, Issue 2, 2006, Pages 21-24

  Cavagna, Mario ^a,b   Dzik, Artur ^a   Freitas, Gilberto C ^a   Soares, Jonathas B ^a   De Pawn, Karen ^a   Sales, Andrea L M ^a   Andrade, Priscila C ^a   Mantese, João C ^a   Gebrim, Luis H ^a  

^a Hospital Perola Byington   (Brazil)

^b NONE   (Brazil)

Author keywords

Fixed dose stimulation protocol; Follitropin ; GnRH agonist; Ovarian stimulation; Recombinant FSH

Indexed keywords

CHORIONIC GONADOTROPIN; GONADORELIN AGONIST; LEUPRORELIN; PROGESTERONE; RECOMBINANT CHORIONIC GONADOTROPIN; RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FEMALE INFERTILITY; FERTILIZATION; FERTILIZATION IN VITRO; HUMAN; HYPOPHYSIS; INFERTILITY THERAPY; INTRACYTOPLASMIC SPERM INJECTION; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; OOCYTE MATURATION; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; OVARY; OVULATION; PREGNANCY; TECHNIQUE;

EID: 33747195068     PISSN: 15175693     EISSN: 15180557     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Albuquerque LE, Saconato H, Maciel MC et al. - Depot versus daily administration of GnRH agonist protocols for pituitary desensitization in assisted reproduction cycles: a Cochrane Review. Hum. Reprod. 10: 2008-2017, 2003.
2. Balasch J, Penarrubia J, Fabregues F et al. - Ovarian responses to recombinant FSH or HMG in normogonadotrophic women following pituitary desensitization by a depot GnRH agonist for assisted reproduction. Reprod. Biomed. Online 7: 35-42, 2003.
3. Bassett RM, Driebergen R - Continued improvements in the quality and consistency of follitropin alfa, recombinant human FSH. Reprod. Biomed. Online 10: 169-177, 2005.
4. Bergh C. - Recombinant follicle stimulating hormone. Hum. Reprod. 14: 1418-1420, 1999.
5. Cheon KW, Byun HK, Yang KM et al. - Efficacy of recombinant human follicle-stimulating hormone in improving oocyte quality in assisted reproductive techniques. J. Reprod. Med. 49: 733-738, 2004.
6. Cheung LP, Lam PM, Lok IH et al. - GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial. Hum. Reprod. 20: 616-621, 2005.
7. Cohen J. - A short review of ovarian stimulation in assisted reproductive techniques. Reprod. Biomed. Online 6: 361-366, 2003.
8. Dal Prato L, Borini A, Cattoli M et al. - GnRH analogs: depot versus short formulations. Eur. J. Obstet. Gynecol. Reprod. Biol. 115 (Suppl. 1): S40-S43, 2004.
9. Daya S. - Updated meta-analysis of recombinant follicle-stimulating hormone (FSH) versus urinary FSH for ovarian stimulation in assisted reproduction. Fertil. Steril. 77: 711-714, 2002.
10. Eldar-Geva T, Robertson DM, Cahir N et al. - Relationship between Serum Inhibin A and B and ovarian follicle development after a daily fixed dose administration of recombinant follicle-stimulating hormone. J. Clin. Endocrinol. Metab. 85: 607-613, 2000.
11. Goldfarb JM, Desai N. - Follitropin-alpha versus human menopausal gonadotropin in an in vitro fertilization program. Fertil. Steril. 80: 1094-1099, 2003.
12. Harrison RF, Jacob S, Spillane H et al. - A prospective randomized clinical trial of differing starter doses of recombinant follicle-stimulating hormone (follitropin-beta) for first time in vitro fertilization and intracytoplasmic sperm injection treatment cycles. Fertil. Steril. 75: 23-31, 2001.
13. Hohmann FP, Macklon NS, Fauser BC. - A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. J. Clin. Endocrinol. Metab. 88: 166-173, 2003.
14. Hoomans EH, Andersen AN, Loft A et al. - A prospective, randomized clinical trial comparing 150 IU recombinant follicle stimulating hormone (Puregon) and 225 IU highly purified urinary follicle stimulating hormone (Metrodin-HP) in a fixed-dose regimen in women undergoing ovarian stimulation. Hum. Reprod. 14: 2442-2447, 1999.
15. Hoomans EH, Mulder BB. - A group-comparative, randomized, double-blind comparison of the efficacy and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon) in Asian women undergoing ovarian stimulation for IVF/ICSI. J. Assist. Reprod. Genet. 19: 470-476, 2002.
16. Hurst BS, Tucker KE, Schlaff WD. - A minimally monitored assisted reproduction stimulation protocol reduces cost without compromising success. Fertil. Steril. 77: 98-100, 2002.
17. Latin-American Puregon IVF Study Group. - A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro fertilization. Fertil. Steril. 76: 950-956, 2000.
18. Ng EHY, Yeung WSB, Ho PC. - Comparison of two dosages of recombinant follice stimulating hormone in Chinese women undergoing controlled ovarian stimulation: prospective randomised double-blind study. Hong Kong Med. J. 6: 368-374, 2000.
19. Out HJ, Mannaerts BM, Driessen SG, Bennink HJ. - A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization. Hum. Reprod. 10: 2534-2540, 1995.
20. Out HJ, Lindenberg S, Mikkelsen AL, et al. - A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation. Hum. Reprod. 14: 622-627, 1999.
21. Out HJ, Braat DD, Lintsen BM et al. - Increasing the daily dose of recombinant follicle stimulating hormone (Puregon) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation. Hum. Reprod. 15: 29-35, 2000.
22. Out HJ, Rutherford A, Fleming R et al. - A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction. Hum. Reprod. 19: 90-95, 2004.
23. Palagiano A, Nesti E, Pace L. - FSH: urinary and recombinant. Eur. J. Obstet. Gynecol. Reprod. Biol. 115 (Suppl. 1): 330-33, 2004.
24. Pruksananonda K, Suwajanakorn S, Sereepapong W, Virutamasen P. - Comparison of two different fixed doses of follitropin-beta in controlled ovarian hyperstimulation: A prospective randomized, double blind clinical trial. J. Med. Assoc. Thai. 87: 1151-1155, 2004.
25. Silverberg K, Daya S, Auray JP et al. - Analysis of the cost effectiveness of recombinant versus urinary follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection programs in the United States. Fertil. Steril. 77: 107-13, 2002.
26. Shoham Z, Insler V. - Recombinant technique and gonadotropin production: new era in reproductive medicine. Fertil. Steril. 66: 187-201, 1996.
27. Yong PY, Brett S, Baird DT, Thong KJ. - A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone (Gonal-F) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment. Fertil. Steril. 79: 308-315, 2003.